Daily Financial News - Australia

Brokers suggest the market has overreacted to QBE’s update, given the progress made in 2018 and the cost reductions outlined for the next three years.

Is Australia’s housing market a source of vulnerability for the economy?

Delays in infrastructure activity and an uncertain housing outlook have cast a shadow over Adelaide Brighton, which has downgraded earnings estimates for 2018.

Australia’s prudential regulator has punished IOOF and investors, in turn, now punish the stock. The acquisition of the ANZ wealth business hangs in limbo.

Revenue growth in core plasma products is still expected as CSL embarks on new classes of therapy in its R&D pipeline.

ResMed will acquire Propeller Health, which provides connected care for patients with COPD and asthma. Brokers believe the acquisition puts ResMed at the forefront of this market.

While Ansell is targeting savings by closing three manufacturing facilities, raw material costs remain the key risk for the earnings outlook.

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.

Metcash faces challenges while striving for a growth strategy after a focus on cost reductions, and brokers suspects FY20 will still be tough.

Coca-Cola Amatil will have another year of transition in 2019, recognising the need to invest in sales and marketing after cutting deeply into its cost base.